Pharma stock jumps after receiving approval from USFDA for antifungal and dandruff shampooPharma stock jumps after receiving approval from USFDA for antifungal and dandruff shampoo

Introduction:

Pharma stock has received final USFDA approval for Ketoconazole Shampoo, 2%, used to treat dandruff and fungal infections. The product, with annual sales of USD 68.89 million, will be manufactured in Ahmedabad, boosting the company’s growth and global market presence.

Share Price movement of Zydus Lifesciences:

On March 10, 2025, Zydus Lifesciences Limited opened at ₹900.80, reaching a high of ₹911.15 and a low of ₹894.00, up 0.25% from its previous close of ₹900.80. The stock is currently trading at ₹903.05, with a market cap of ₹90,867.96 crore.

Zydus Lifesciences share price rise:

Zydus Lifesciences Limited has received final approval from the USFDA to manufacture Ketoconazole Shampoo, 2%. This approval pertains to the USRLD: Nizoral® Shampoo, 2%, a product used to treat dandruff, fungal infections, and other skin conditions.

The shampoo will be manufactured at Zydus’ topical manufacturing site in Changodar, Ahmedabad. With annual sales of USD 68.89 million in the United States as of January 2025, the product is expected to contribute significantly to the company’s growth.

Zydus now holds 418 approvals and has filed 483 ANDAs since FY 2003-04. This approval further strengthens Zydus’ portfolio and underscores its capabilities in the global pharmaceutical market.

Also Read: Infra stock jumps after it receives order worth ₹11 Cr from Bhavnagar Municipal Corporation

Recent news About Zydus Lifesciences:

The company reported a 30% year-on-year increase in net profit for the quarter ending December 31, 2024, totaling ₹1,023.5 crore. This growth was driven by strong performance in the U.S. market, with revenues increasing by 17% year-on-year.

Stock performance of Zydus Lifesciences for Period of 1 week, 6 months and 1 year:

Zydus Lifesciences’ stock has gained 3.49% over the past week, showing positive short-term performance. However, over the last six months, it has declined by 19%, reflecting challenges. For the past year, the stock has dropped by 7.78%, indicating a period of overall underperformance.

Also Read: Penny stock hits 5% upper circuit after company to explore real estate potential of land

Shareholding pattern of Zydus Lifesciences:

All values in %	Dec-24	Sep-24	Jun-24
Promoters	74.98	74.98	74.98
FII	7.53	7.52	5.59
DII	10.66	10.64	12.63
Retail & others	6.85	6.85	6.81

About Zydus Lifesciences:

Zydus Lifesciences is a leading global pharmaceutical company that specializes in manufacturing generic medications, active pharmaceutical ingredients (APIs), and over-the-counter products. The company focuses on innovation, research, and expanding its global market presence to improve healthcare and patient outcomes worldwide.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.